Search research articles
Contact Us
Filters
Showing results (161-170 of 205) with videos related to
Page
of 21
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update
Evan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
Science Immunology
|
July 19, 2020
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding
Lawrence P Andrews, Ashwin Somasundaram, Jessica M Moskovitz, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
July 25, 2017
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Genevieve J Kaunitz, Tricia R Cottrell, Mohammed Lilo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, et al.
Cancer Immunology Research
|
May 19, 2022
Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells
Ashwin Somasundaram, Anthony R Cillo, Caleb Lampenfeld, et al.
Kidney International
|
June 11, 2016
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Frank B Cortazar, Kristen A Marrone, Megan L Troxell, et al.
Journal of Translational Medicine
|
March 5, 2024
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
Shuming Chen, Tracee L McMiller, Abha Soni, et al.
Journal for Immunotherapy of Cancer
|
December 25, 2025
AstroID resource: a scalable, relational database structure for longitudinal biomarker discovery
Elizabeth M Will, Benjamin F Green, Scott Carey, et al.
NEJM Evidence
|
February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V Long, F Stephen Hodi, Evan J Lipson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Evan J Lipson, Sonia Dolfi, Hao Tang, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 205) with videos related to
Sort By:
Page
of 21
European Journal of Cancer (Oxford, England : 1990)
|
June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update
Evan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
Science Immunology
|
July 19, 2020
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding
Lawrence P Andrews, Ashwin Somasundaram, Jessica M Moskovitz, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
July 25, 2017
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Genevieve J Kaunitz, Tricia R Cottrell, Mohammed Lilo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, et al.
Cancer Immunology Research
|
May 19, 2022
Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells
Ashwin Somasundaram, Anthony R Cillo, Caleb Lampenfeld, et al.
Kidney International
|
June 11, 2016
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Frank B Cortazar, Kristen A Marrone, Megan L Troxell, et al.
Journal of Translational Medicine
|
March 5, 2024
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
Shuming Chen, Tracee L McMiller, Abha Soni, et al.
Journal for Immunotherapy of Cancer
|
December 25, 2025
AstroID resource: a scalable, relational database structure for longitudinal biomarker discovery
Elizabeth M Will, Benjamin F Green, Scott Carey, et al.
NEJM Evidence
|
February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V Long, F Stephen Hodi, Evan J Lipson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Evan J Lipson, Sonia Dolfi, Hao Tang, et al.
Page
of 21